Home › Funds › Spruce Street Capital LP › RLAY
Spruce Street Capital LP position in RLAY
RELAY THERAPEUTICS INC · Health Care
Spruce Street Capital LP reported holding 2,984,125 shares of RLAY (RELAY THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$53.9M, representing 8.56% of its reported portfolio and ranking #2 among its reported holdings. Spruce Street Capital LP has disclosed RLAY holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's RLAY position evolved
Spruce Street Capital LP first disclosed a stake in RLAY in Q4 2025 at 2,984,125 shares (US$25.2M). The position peaked in Q2 2026 at 2,984,125 shares, worth US$55.8M. Across 4 filings, Spruce Street Capital LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,984,125 shares valued at US$53.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.98M | $25.25M | New |
| Q1 2026 | 2.98M | $29.69M | Hold |
| Q2 2026 | 2.98M | $55.83M | Hold |
| Q3 2026 | 2.98M | $53.86M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLAY and 13F data
RLAY (RELAY THERAPEUTICS INC) is a Health Care company. 60 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLAY
- SB INVESTMENT ADVISERS (UK) LTD 27.90M sh · $522.10M · Q2 2026
- Casdin Capital 16.04M sh · $300.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 14.11M sh · $263.93M · Q2 2026
- Commodore Capital LP 12.00M sh · $224.52M · Q2 2026
- Nextech Invest Ltd. 6.78M sh · $126.79M · Q2 2026
- Bellevue Group AG 6.19M sh · $115.74M · Q2 2026
- TCG Crossover Management, LLC 4.27M sh · $79.95M · Q2 2026
- Kynam Capital Management, LP 3.30M sh · $61.74M · Q2 2026
- Siren, L.L.C. 3.26M sh · $58.90M · Q3 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $52.89M · Q2 2026
- MPM BioImpact LLC 2.42M sh · $45.20M · Q2 2026
- Elmind Capital, LP 1.47M sh · $27.42M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held RLAY?
Spruce Street Capital LP has disclosed RLAY holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in RLAY?
As of Q3 2026, Spruce Street Capital LP holds 2.98M shares of RLAY (RELAY THERAPEUTICS INC), valued at $53.86M, representing 8.56% of its reported portfolio and ranking #2.
Has Spruce Street Capital LP been buying or selling RLAY?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in RLAY. The position peaked in Q2 2026 at 2.98M shares.
Which other funds hold RLAY?
Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.